Close Menu

NEW YORK (GenomeWeb) – Researchers from the Dana-Farber Cancer Institute, the Broad Institute, and elsewhere have identified new genomic features of tumors that respond to immune checkpoint therapy to supplement existing biomarkers, such as tumor mutational burden.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.